WO2006008259A1 - Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitabale for the treatment of neurodegenerative disorders - Google Patents

Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitabale for the treatment of neurodegenerative disorders Download PDF

Info

Publication number
WO2006008259A1
WO2006008259A1 PCT/EP2005/053345 EP2005053345W WO2006008259A1 WO 2006008259 A1 WO2006008259 A1 WO 2006008259A1 EP 2005053345 W EP2005053345 W EP 2005053345W WO 2006008259 A1 WO2006008259 A1 WO 2006008259A1
Authority
WO
WIPO (PCT)
Prior art keywords
halo
optionally substituted
het
alkyl
pyridinyl
Prior art date
Application number
PCT/EP2005/053345
Other languages
French (fr)
Inventor
Miroslav Cik
Gaston Stanislas Marcella Diels
Guy Rosalia Eugeen Van Lommen
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Priority to EP05769847A priority Critical patent/EP1771445A1/en
Priority to JP2007520836A priority patent/JP2008506669A/en
Priority to MX2007000615A priority patent/MX2007000615A/en
Priority to CA002572821A priority patent/CA2572821A1/en
Priority to AU2005263718A priority patent/AU2005263718A1/en
Priority to EA200700140A priority patent/EA200700140A1/en
Priority to US11/632,510 priority patent/US20070299109A1/en
Publication of WO2006008259A1 publication Critical patent/WO2006008259A1/en
Priority to IL180703A priority patent/IL180703A0/en
Priority to NO20070884A priority patent/NO20070884L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Formula (I’’), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof.

Description

DIMERIC COMPOUNDS OF PIPERIDINE, PIPERAZINE OR MORPHOLINE OR THEIR 7-MEMBERΞD ANALOGS SUITABLE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
Neurotrophins, such as nerve growth factor (NGF), brain derived growth factor 5 (BDNF), neurotrophic factor 3 (NT3) and neurotrophic factor 4 (NT4) mediate the survival, differentiation, growth and apoptosis of neurons. They bind to two structurally unrelated cell surface receptors, tropomyosin related kinase (Trk) receptors and p75 neurotrophin receptor (p75NTR) (Kaplan D. R. and Miller F. D. (2000) Current Opinion in Neurobiology 10, 381-391). By activating those two type of receptors, neurotrophins
10 mediate both, positive and negative survival signals. NGF binds with high affinity to TrkA, BDNF has high affinity for TrkB, NT-3 binds preferentially to TrkC. Binding of neurotrophins to Trk receptors is necessary for neurotrophic activity. P75NTR, a member of TNF receptor superfamily was first neurotrophin receptor to be described. It binds all neurotrophins with similar affinity. P75NTR was first described as a positive
15 modulator of TrkA activity. Their co-expression lead to an increase of NGF affinity for TrkA receptors, NGF-mediated TrkA activation and ligand specificity. P75NTR can also signal on it own and promote cell death in a variety of cell types. (Coulson E. J., Reid K., and Bartlett P. F. (1999) Molecular Neurobiology 20, 29-44) .
20 Neurotrophins and possible therapeutical relevance
Neurotrophins have a well established role in regulating the survival, differentiation and maintenance of functions of specific and sometimes overlapping neuronal populations. Besides these roles of neurotrophins during embryonic development and
25 adulthood, there is increasing evidence that neurotrophins are involved in processes of neuronal plasticity. These studies suggest several potential therapeutic application. It has been shown that neurotrophins can protect and rescue certain neuronal populations in in vitro and in vivo models of various neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis (ALS), stroke
30 and peripheral neuropathies (Chao M. V. (2003) Nature Reviews Neuroscience 4, 299- 309; Dawbarn D. and Allen S. J. (2003) Neuropathology & Applied Neurobiology 29, 211-230).
In addition, accumulating evidence in last few years shows that p75NTR plays a key role in neuronal death that occurs in some of the major disorders of the CNS such as stroke,
35 Alzheimer's, ALS, epilepsy, Spinal Cord Injury (SCI), Multiple Sclerosis (MS), Motor Neuron Disease (MND) and other neurodegenerative diseases (Park et al. (2000) Journal of Neuroscience 20, 9096-9103; Oh et al. (2000) Brain Research 853, 174-185; Lowry et al. (2001) Journal of Neuroscience Research 64, 11-17; Sedel et al. (1999) European Journal ofNeuroscience 11, 3904-3912; Dowling et al. (1999) Neurology 53, 1676-1682) and only recently, NGF was found to play an important role in pain, in particular in post-operative pain after surgery (Zahn et al. 2004, The Journal of Pain 5(3); 157-163). For these reasons small molecules that enhance the activity of neurotrophins, or that have similar effects as neurotrophins, are of great interest (Massa et al, (2002) Journal of Molecular Neuroscience 19, 107-111; Saragovi and Burgess (1999) Expert Opinion on Therapeutic Patents 9, 737-751).
Experimental evidence
Peripheral neurons derived from chick embryo dorsal root ganglia (DRQ) are extensively used for in vitro characterizations of neurotrophic factors and other molecules with neurotrophic activities. The survival of chick DRG neurons can be supported by different neurotrophic factors, such as nerve growth factor (NGF) (Levi- Montalcini R. and Angeletti P. U. (1968) Physiological Reviews 48, 534-569) brain derived neurotrophic factor (Barde Y. A. et al. (1982) EMBO Journal 1, 549-553) and ciliary neurotrophic factor (CNTF) (Barbin G. et al. (1984) Journal ofNeurochemistry 43, 1468-1478). Small molecules with the neurotrophic activity, such as K-252a and CEP-1347 also support the survival of DRG neurons (Borasio G. D. (1990) Neuroscience Letters 108, 207-212; Borasio G. D. et al. (1998) Neuroreport 9, 1435- 1439). The primary culture of dissociated DRG neurons from chicken embryo at embryonic day 8-10 has been used successfully in a number of laboratories as a bioassay for neurotrophins. The assay determines the survival effect of compounds on DRG neurons and is based on a fluorimetric Calcein-AM measurement (He W. et al. (2002) Bioorganic & Medicinal Chemistry 10, 3245-3255). This assay, which addresses the functional response of neurons as a quantitative measure of survival, may have the advantage of few false positive.
HTS campaign using a primary culture of chicken DRG neurons, resulted in the identification of compounds with neurotrophic activity (neuronal survival). The most potent compounds identified belong to a series of "symmetrical compounds".
This invention concerns compounds of formula (I)
Figure imgf000004_0001
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
n represents 0, 1 or 2; m represents 0, 1 , 2 or 3; Z represent C, Ν or O, in particular Z represents CH2;
-X- represents C2-4alkynyl, Ci-i2alkyl optionally substituted with hydroxy or X represents a divalent radical of the formula
Figure imgf000004_0003
Figure imgf000004_0002
H XX (a) (b) (C)
wherein; -Xi- represents Ci.^alkyl, phenyl or a,4ivalent radical selected from the group consisting of
Figure imgf000004_0004
-X2- represents Ci-12alkyl, Ci^alkyloxyCMalkyl, phenyl or a divalent
Figure imgf000004_0005
-X3- represents phenyl or a divalent radical selected from the group
Figure imgf000004_0006
R1 and R2 each independently represents hydrogen, C1-4alkyl, C]-4alkyl-carbonyl- ,
Figure imgf000004_0007
substituted with Her2 or Ar3; or R1 and R2 taken together with the nitrogen atom with which they are attached form a heterocycle selected from pyrimidinyl, indolyl, indolinyl, indazolyl, imidazolinyl, imidazolidinyl, benzoxazolyl, benzimidazolyl, quinazolinyl, qυinolinyl or benzthiazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of carbonyl,
Ar5, amino, mono- or di-substituted (Ci_4alkyl)-amino-, hydroxy, halo,
Figure imgf000005_0002
Ci-talkyl, and phenyl ;
R3 independently represents hydroxy
Figure imgf000005_0001
Het1 represents a heterocycle selected from pyridinyl, indolinyl, benzimidazolyl, benzthiazolyl, thiazolyl, pyridinyl, benzisoxazolyl, benzoxazolyl, oxadiazolyl or thiadiazolyl wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Ar4,
Figure imgf000005_0003
and
Figure imgf000005_0004
substituted with halo; Het2 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, benzisoxazolyl, benzoxazolyl or thiadiazolyl wherein said Het2 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Het4,
Figure imgf000005_0005
Chalky]-,
Figure imgf000005_0006
and
Figure imgf000005_0007
substituted with halo;
Het3 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl;
Het4 represents a heterocycle Selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl wherein said Het4 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo,
Figure imgf000005_0008
Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo, amino, Het3, Ci4alkylcarbonyl-, Ci^alkyl, Ci^alkyloxy- or Ci^alkyl substituted with one, two or three halo substituents; in particular Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo, C^alkyl or
Figure imgf000005_0009
Ar4 represents phenyl optionally substituted with halo, Ci^alkyl, C^alkyloxy- or Ci^alkyl substituted with one, two or three halo substituents;
Ar5 represents phenyl optionally substituted with Q^alkyloxy- or Cs-βcycloalkyloxy-.
As used herein before, the terms;
- oxo or carbonyl refers to (=0) that forms a carbonyl moiety with the carbon atom to which it is attached; - halo is generic to fluoro, chloro, bromo and iodo;
- CMalkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1- methylethyl, 2-methylpropyl, 2,2-dimethylethyl and the like; - C,.6alkyl is meant to include Ci^alkyl and the higher homologues thereof having 6 carbon atoms such as, for example hexyl, 1 ,2-dimethylbutyl, 2-methylpentyl and the like;
- Ci^alkyloxy defines straight or branched saturated hydrocarbon radicals having from 1 to 4 carbon atoms and 1 oxygen atom such as methoxy, ethoxy, propyloxy, butyloxy, 1-methylethyloxy, 2-methylpropyloxy and the like.
The heterocycles as mentioned in the above definitions and hereinafter, are meant to include all possible isomeric forms thereof, for instance triazolyl also includes 1,2,4- triazolyl and 1,3,4-triazolyl; oxadiazolyl includes 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl and 1,3,4-oxadiazolyl; thiadiazolyl includes 1,2,3-thiadiazolyl, 1,2,4- thiadiazolyl, 1,2,5-thiadiazolyl and 1,3,4-thiadiazolyl.
Futher, the heterocycles as mentioned in the above definitions and hereinafter may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate. Thus, for example, when the heterocycle is imidazolyl, it may be a 1 -imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl; when it is thiazolyl, it may be 2-thiazolyl, 4-thiazolyl and 5-thiazolyl; when it is benzothiazolyl, it may be 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl and 7-benzothiazolyl.
The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms, which the compounds of formula (I), are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic,/7-toluenesulfonic, cyclamic, salicylic, ^-aminosalicylic, pamoic and the like acids. The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic base addition salt forms which the compounds of formula (I), are able to form. Examples of such base addition salt forms are, for example, the sodium, potassium, calcium salts, and also the salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, N-methyl-D-glucarnine, hydrabamine, amino acids, e.g. arginine, lysine.
Conversely said salt forms can be converted by treatment with an appropriate base or acid into the free acid or base form.
The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I), as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.
The term stereochemically isomeric forms as used hereinbefore defines the possible different isomeric as well as conformational forms which the compounds of formula (I), may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically and conformationally isomeric forms, said mixtures containing all diastereomers, enantiomers and/or conformers of the basic molecular structure. All stereochemically isomeric forms of the compounds of formula (I), both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.
The N-oxide forms of the compounds of formula (I), are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called N-oxide.
A particular group of the compounds of the present invention consist of those compounds of formula (I) wherein one or more of the following restrictions apply; -X- represents C2-4alkynyl5 Ci-i2alkyl optionally substituted with hydroxy or X represents a divalent radical of the formula
Figure imgf000007_0001
(a) (b) (C) wherein; -X]- represents Q-^alkyl, phenyl or a divalent radical selected from
Figure imgf000008_0001
-X2- represents Ci-^alkyl, CMalkyloxyCi^alkyl, phenyl or a divalent
radic
Figure imgf000008_0002
-X3- represents phenyl or a divalent radical selected from the group consisting of
Figure imgf000008_0003
n represents 1 ; m represents O5 1 or 2; in particular m represents 0;
R1 and R2 each independently represent hydrogen, C^alkyl, Ar'-carbonyl, Het1, Ar2 or
Figure imgf000008_0004
optionally substituted with Het2 or Ar3; or R1 and R2 taken together with the nitrogen atom to which they are attached form a heterocycle selected from indolyl, indolinyl, benzimidazolyl, benzthiazolyl, benzisoxazolyl or oxodiazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy,
Figure imgf000008_0005
carbonyl, Ar5 and halo; in particular R1 and R2 taken together with the nitrogen atom with which they are attached form a heterocycle selected from indolinyl, benzimidazolyl, or benzthiazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Ci-4alkyl, Ci^alkyloxycarbonyl- and phenyl ; Het ' represents a heterocycle selected from pyridinyl, indolinyl, indolyl, benzthiazolyl, benzimidazolyl, thiazolyl, thiadiazolyl or benzisoxazolyl wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Ar4, C i^alkyloxy carbonyl-, C^aUcyl and Ci-4alkyloxy-, said Ci-4alkyloxy- being optionally substituted with halo; in particular Het1 represents a heterocycle selected from pyridinyl, indolinyl, benzimidazolyl, benzthiazolyl, thiazolyl, or thiadiazolyl wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Ar4, C
Figure imgf000008_0006
i^alkyloxycarbonyl-, Ci4alkyloxy- and CMalkyloxy- substituted with halo; Het2 represents a heterocycle selected from thiophenyl, fiiranyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl;
Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo,
Ci-4alkyl,
Figure imgf000009_0001
substituted with one, two or three halo substituents; in particular Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo, C^alkyl or C^alkyloxy-; in particular Ar1 represents phenyl optionally substituted with halo, amino, C^alkyl or
Figure imgf000009_0002
Ar2 represents phenyl optionally substituted with halo, C1-4alkyl, Ci-4alkyloxy- or Het'-Ci^alkyl-carbonyl-; in particular Ar2 represents phenyl substituted with halo; and Ar3 represents phenyl optionally substituted with halo,
CMalkyl or C^alkyloxy-;
Ar represents phenyl optionally substituted with halo, Ci-4alkyl,
Figure imgf000009_0003
or substituted with one, two or three halo substituents;
Ar5 represents phenyl optionally substituted with Ci_4alkyloxy- or Ca^cycloalkyloxy-.
An interesting group of compounds are those compounds of formula (I')
Figure imgf000009_0004
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n represents 1 or 2; m represents 0, 1, 2 or 3;
-X- represents C2-4alkynyl, Cu^alkyl optionally substituted with hydroxy or X represents a divalent radical of the formula
Figure imgf000009_0005
(a) (b) (C)
wherein; -Xi- represents Q.nalkyl, phenyl or a divalent radical selected from the group
Figure imgf000009_0006
-X2- represents Ci.i2alkyl, C1-4alkyloxyCi-4alkyl, phenyl or a divalent
radic
Figure imgf000010_0001
al of formula
-X3- represents phenyl or a divalent radical selected from the group
consisting of tø> ' ^ O ^ O1) and W
R1 and R2 each independently represents hydrogen, C^alkyl, CMalkyl-carbonyl- , Ax'-carbonyl-, Het1, Ar2 or C1.4alkyl-carbonyl- substituted with Het2 or Ar3; or
R1 and R2 taken together with the nitrogen atom with which they are attached form a heterocycle selected from pyrimidinyl, indolyl, indolinyl, indazolyl, imidazolinyl, imidazolidinyl, benzoxazolyl, benzimidazolyl, quinazolinyl, quinolinyl or benzthiazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of carbonyl, Ar5, amino, mono- or di-substituted (CiJtalkyl)-amino-, hydroxy, halo,
Figure imgf000010_0002
and phenyl ;
R3 independently represents hydroxy or C^alkyloxy-;
Het1 represents a heterocycle selected from pyridinyl, indolinyl, benzimidazolyl, benzthiazolyl, thiazolyl, pyridinyl, benzisoxazolyl, benzoxazolyl, oxadiazolyl or thiadiazolyl wherein said Het1 is optionally substituted with one or where possible twό*6r more substituents selected from the group consisting of hydroxy, halo, Ar4, C^alkyloxycarbonyl-, C^alkyl-, C1-4alkyloxy- and
Figure imgf000010_0003
substituted with halo;
Het2 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, benzisoxazolyl, benzoxazolyl or thiadiazolyl wherein said Het2 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Het4, Ci_4alkyloxycarbonyl-, C1-4alkyl-,
Figure imgf000010_0004
and
Figure imgf000010_0005
substituted with halo;
Het3 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl;
Het4 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl wherein said Het4 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Ci^alkyl- and C]-4alkyloxy-; Ar , Ar2 and Ar3 each independently represent phenyl optionally substituted with halo, amino, Het3,
Figure imgf000011_0001
C^alkyl substituted with one, two or three halo substituents; in particular Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo, Ci-4alkyl or Ci^alkyloxy-;
Ar4 represents phenyl optionally substituted with halo,
Figure imgf000011_0002
C1-4alkyloxy- or
CMalkyl substituted with one, two or three halo substituents; Ar5 represents phenyl optionally substituted with C1-4alkyloxy- or
Cs-βcycloalkyloxy-.
Also of interest are those compounds of formula (F) wherein one or more of the following restrictions apply; n represents 1; m represents 0; R1 and R2 each independently represent hydrogen, Q^alkyl, Ar'-carbonyl, Het1,
Ar2 or Ci-4alkylcarbonyl optionally substituted with Het2 or Ar3; or R1 and R2 taken together with the nitrogen atom to which they are attached form a heterocycle selected from indolyl, indolinyl, benzimidazolyl, benzthiazolyl, benzisoxazolyl or oxodiazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, Ci-4alkyl, carbonyl, Ci^alkyloxycarbonyl-, Ar5 and halo; Het ' represents a heterocycle selected from pyridinyl, indolinyl,r'indolyl, benzthiazolyl, benzimidazolyl, thiazolyl, thiadiazolyl or benzisoxazolyl wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of halo, Ar4, Ci- 4alkyloxycarbonyl-, Ci_4alkyl and
Figure imgf000011_0003
said C^alkyloxy- being optionally substituted with halo;
Het2 represents a heterocycle selected from thiophenyl, fϊiranyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl;
Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo,
Figure imgf000011_0004
substituted with one, two or three halo substituents;
Ar4 represents phenyl optionally substituted with halo,
Figure imgf000011_0005
or Ci_4alkyl substituted with one, two or three halo substituents;
Ar5 represents phenyl optionally substituted with Ci^alkyloxy- or C3-6CyClOaUCyIoXy-. A further group of compounds of formula (I) consist of those compounds of formula (I) wherein one or more of the following restrictions apply; n represents 1; m represents 0; Z represents CH2;
R1 and R2 each independently represent hydrogen, Ci^alkyl, Ar'-carbonyl, Het1,
Ar2 or CMalkylcarbonyl optionally substituted with Het2 or Ar3; or R1 and R2 taken together with the nitrogen atom to which they are attached form a heterocycle selected from indolyl, indolinyl, benzimidazolyl, benzthiazolyl, benzisoxazolyl or oxodiazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, Ci^alkyl, carbonyl, Ci^alkyloxycarbonyl-,
Ar5 and halo;
Het ' represents a heterocycle selected from pyridinyl, indolinyl, indolyl, benzthiazolyl, benzimidazolyl, thiazolyl, thiadiazolyl or benzisoxazolyl wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of halo, Ar4, Ci- 4alkyloxycarbonyl-,
Figure imgf000012_0001
being optionally substituted with halo; Her2 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl; Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo,
Figure imgf000012_0002
substituted with one, two or three halo substituents; Ar4 represents phenyl optionally substituted with halo,
Figure imgf000012_0003
Ci^alkyloxy- or
Ci^alkyl substituted with one, two or three halo substituents; Ar5 represents phenyl optionally substituted with C^alkyloxy- or
Cs-βcycloalkyloxy-.
Another interesting group of compounds according to the invention are those compounds of formula (I) or formula (I') wherein one or more of the following restrictions apply; n represents 1; m represents 0; Z represents C, in particular CH2 for those compounds of formula (I);
R1 and R2 each independently represents hydrogen,
Figure imgf000012_0004
Ar'-carbonyl-, Het1, Ar2 or Ci-4alkylcarbonyl- substituted with Het2 or Ar3; or R1 and R2 taken together with the nitrogen atom to which they are attached form a heterocycle selected from indolyl, indolinyl, or benzimidazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of carbonyl, hydroxy or halo; Het1 represents a heterocycle selected from pyridinyl, indolinyl, benzthiazolyl, thiazolyl, or thiadiazolyl, wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of halo, Ar4, C1-4alkyloxycarbonyl- and Ci^alkyloxy- substituted with halo;
Het2 represents thiophenyl; Ar1 represents phenyl optionally substituted with halo or
Ar2 represents phenyl optionally substituted with halo or
Ar3 represents phenyl optionally substituted with halo or
Figure imgf000013_0001
Ar4 represents phenyl optionally substituted with Ci-4alkyl-.
Also of interest are those compounds of formula (I) or (I') wherein; m represents 0; Z represents C or N, in particular C, more in particular CH2 for those compounds of formula (I); n represents 1; -X- represents C2-4alkynyl, Ci-i2alkyl optionally substituted with hydroxy or -X- represents a divalent radical of the formula (a), (b) or (c) as defined hereinbefore wherein; -Xi- represents
Figure imgf000013_0002
or a divalent radical selected from (d) or (e) as defined for the compounds of formula (I) hereinbefore; -X2- represents C1-12alkyl,
Figure imgf000013_0003
phenyl or a divalent radical of formula (g) as defined for the compounds of formula (I) hereinbefore;
-X3- represents phenyl or a divalent radical selected from the (g), (h) and (i) as defined for the compounds of formula (I) hereinbefore;
R1 and R2 each independently represent hydrogen,
Figure imgf000013_0004
or R1 and R2 taken together with the nitrogen atom to which they are attached form a heterocycle selected from indolyl, indolinyl or benzimidazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of carbonyl, hydroxy or halo;
Het1 represents a heterocycle selected from pyridinyl, indolinyl or benzthiazolyl wherein said Het1 is optionally substituted with halo, Ar4 or
Figure imgf000013_0005
Het2 represents thiophenyl;
Ar1 represents phenyl optionally substituted with halo or Ci^alkyloxy-; Ar2 represents phenyl optionally substituted with halo or Ci.4alkyloxy; Ar3 represents phenyl optionally substituted with halo or C^alkyl; or Ar4 represents phenyl optionally substituted with Ci.4alkyl-.
It is accordingly an object of the present invention to provide the compounds of formula (I")
Figure imgf000014_0001
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
-X- represents C^alkynyl, Q.πalkyl optionally substituted with hydroxy or X represents a divalent radical of the formula
Figure imgf000014_0002
(a) (b) (C)
wherein; -Xr represents Ci-ualkyl, phenyl or a divalent radical selected from
Figure imgf000014_0003
phenyl or a divalent
Figure imgf000014_0004
-X3- represents phenyl or a divalent radical selected from the group consisting of
Figure imgf000014_0005
R1 and R2 each independently represents hydrogen, Q^alkyl, C^aHcyl-carbony!- , Ar'-carbonyl-, Het1, Ar2 or C^alkyl-carbonyl- substituted with Her2 or Ar3; or R1 and R2 taken together with the nitrogen atom with which they are attached form a heterocycle selected from indolinyl, benzimidazolyl, or benzthiazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Chalky!,
CMalkyloxycarbonyl- and phenyl ; Het1 represents a heterocycle selected from pyridinyl, indolinyl, benzimidazolyl, benzthiazolyl, thiazolyl, pyridinyl, or thiadiazolyl wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Ar4,
Figure imgf000015_0001
Ci-4alkyloxy- and Ci^alkyloxy- substituted with halo; Het2 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl;
Ar1 represents phenyl optionally substituted with halo, C
Figure imgf000015_0002
^alkyl or Ar2 represents phenyl optionally substituted with halo,
Figure imgf000015_0003
or Ci^alkyloxy-; in particular Ar2 represents phenyl substituted with halo;
Ar3 represents phenyl optionally substituted with halo,
Figure imgf000015_0004
or Ci-4alkyloxy-; Ar4 represents phenyl optionally substituted with halo, Q^alkyl or Ci^alkyloxy-.
In a further embodiment the compounds of the present invention consist of those compounds of formula (I) wherein n represents 1 , m represents 0, Z represents C, in particular CH2 and the NR1R2 substituent is in the para position vis-a-vis the N-atom of the piperidine ring. Said NR1R2 substituent preferably consists of benzthiazolyl optionally substituted with halo or phenyl or R1 and R2 each independently represent hydrogen, Het1, Ar2,
Figure imgf000015_0005
or methylphenylcarbonyl and R2 or R1 respectively, represents pyridinyl or benzthiazolyl.
In an even further embodiment the compounds of the present invention are selected from the compounds according to formulae (A) - (O) below:
Figure imgf000015_0006
Figure imgf000016_0001
The dimeric compounds of this invention can be prepared by any of several standard synthetic processes commonly used by those skilled in the art of organic chemistry and described for instance in; "Introduction to organic chemistry" Streitweiser and Heathcock- Macmillan Publishing Co., Inc. - second edition - New York.
In general, for those compounds where X represents a C2-4alkynyl or an optionally substituted Q.πalkyl, the dimeric compounds are obtained by a nucleofilic substitution reaction between the appropriate secondary amine (i) with an alkylhalide (scheme 1) under basic reaction conditions, such as for example described in "Introduction to organic chemistry" Streitweiser and Heathcock - Macmillan Publishing Co., Inc. - second edition - New York, page 742 — section 24.6.
Figure imgf000017_0001
Wherein m, Z, X, R > I , τ R>2 and R are defined as for the compounds of formula (I)
For those compounds where X represents a divalent radical of formula (a) the urea derivatives of formula (Iii) are prepared by reacting the appropriate secondary amine with an isocyanate of general formula (ii) under art known conditions such as for example described in "Advanced Organic Chemistry" Jerry March - John Wiley & Sons, Inc. — third edition— New York, page 802 - section 6-17.
Scheme 2
Figure imgf000017_0002
Wherein m, Z, X1, R',R2and R3 are defined as for the compounds of formula (I)
Those compounds where X represents a divalent radical of formula (b), the amide derivatives of formula (Iiii) are prepared by reacting the appropriate secondary amine with an acylhalide of general formula (iii) under art known conditions such as for example described in "Advanced Organic Chemistry" Jerry March — John Wiley & Sons, Inc. - third edition -New York, page 370 - section 0-54. Alternatively the amide derivatives of formula (Iiii) are obtained by acylation of the appropriate secondary amine with an bisanhydride of general formula (iv) under art known conditions such as for example described in "Advanced Organic Chemistry" Jerry March - John Wiley & Sons, Inc. - third edition - New York, page 371 - section 0-55, or by acylation of the appropriate secondary amine with an ester of general formula (v) under art known conditions such as for example described in "Advanced Organic Chemistry" Jerry March - John Wiley & Sons, Inc. - third edition - New York, page 375 - section 0-57.
OR'
Figure imgf000018_0001
Wherein X1 is defined as for the compounds of formula (I) and R' represents R11R111N-
In a further alternative the active ester intermediates of formula (v') (see scheme 3) are obtained by reaction of the appropriate secondary amine with a carboxylic acid (xviii) in the presence of reagantia, i.e. coupling reagents such as for example N5N'- Dicyclohexylcarbodiimide (DCC), N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDCI), (Benzotriazol-l-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) or O-(Benzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (HBTU), which in a first step convert the carboxylic acid in an activated form. This reaction is preferably performed in the presence of a further hydroxylamine additive, such as 1-hydroxybenzotriazole (HOBt) or 7-aza- 1 -hydroxybenzotriazole (HOAt), to prevent dehydration of the carboxamide residues thus obtained.
Figure imgf000019_0001
Wherein m, Z, X2, R , R and R are defined as for the compounds of formula (I), R' represents a C ^alkyl, preferably ethyl and wherein halo represents a halogen such as for example Cl, Br and I
Finally, the sulfonamide derivative of formula (Iiv) where X represents a divalent radical of formula (c) are generally prepared by a nucleophilic substitution reaction between the appropriate secondary amine and a sulfonylhalide, preferably a sulfonylchloride of general formula (vi) under art known conditions such as for example described in "Advanced Organic Chemistry" Jerry March - John Wiley & Sons, Inc. — third edition - New York, page 445 - section 0-119.
Figure imgf000020_0001
Wherein m, Z3 X3, R1, R2and R3 are defined as for the compounds of formula (I) and wherein halo represents a halogen such as for example Cl, Br and I, preferably Cl
The appropriate secondary amines as used hereinbefore are either commercially available or in a particular embodiment, prepared departing from 4-piperidone or 4- amino-piperidine wherein the N-atom of the piperidine ring is shielded by means of a protective group such as for example methyloxycarbonyl, benzyl or trialkylsilyl groups.
For those compounds of formula I wherein R1 or R2 represents thiazolyl or benzthiazolyl the secondary amines are prepared according to reaction scheme S. In a first step the aminopiperidine of formula (vii) is converted into the intermediate of formula (ix) by reaction with an isothiocyanate of formula (viii) under art known reaction conditions (see scheme 2 above). For those intermediates where R" represents hydrogen, the compounds of formula (I) are subsequently prepared by the cyclodesulfurization reaction of the thiourea derivative of formula (ix) by the reaction of (ix) with an appropriate alkyl halide (x) in an appropriate reaction-inert organic solvent, e.g., a lower alkanol such as methanol, ethanol, 2-propanol and the like. For those intermediates of formula (ix) where R" does represent optionally substituted phenyl, the cyclodesulfurization reaction is carried out according to art-known procedures, such as for example using bromine in an aqueous hydrobromic acid solution.
Subsequently eliminating the protective group in the thus obtained intermediates of formula (xi) and (xi') respectively, provides the appropriate secondary amines used as intermediates in the synthesis of the dimeric compounds of the present invention. The elimination of the protective group P in (xi, xi') may generally be carried out following art-known procedures such as, for example, by hydrolysis in alkaline or acidic aqueous medium. Scheme 5
Figure imgf000021_0001
Wherein halo represents a halogen such as for example Cl, Br and I; R1 is defined as for the compounds of formula (I); R" represents hydrogen or an optionally substituted phenyl substituent; R1" and Rιv each independently represent hydroxy, halo, Ar4, C1.4alkyloxycarbonyl-, Chalky!-, C^alkyloxy- or CMalkyloxy- substituted with halo, wherein Ar is defined as for the compounds of formula (I)
Alternatively, the appropriate secondary amines are prepared by reductive amination from the piperidone (xii) with an amine of general formula (xiii) to yield the intermediate of formula (xiv). Further substitution of the secondary amine with an alkyl halide (xv) or acyl halide (xvi) under art known conditions (supra) provides the intermediates of formula (xvii) and (xvii') respectively. Subsequently eliminating the protective group in the thus obtained intermediates, provides the appropriate secondary amines used as intermediates in the synthesis of the dimeric compounds of the present invention.
Alternatively the intermediate of formula (xiv) is converted into the thiourea derivative of formula (ix) by reaction with an isothiocyanate of formula (viii) under art known reaction conditions (see sheme 5 above). Subsequent cyelodesulfurization (supra) and deprotection (supra) provides the appropriate secondary amines.
Scheme 6
Figure imgf000022_0001
Wherein halo represents a halogen such as for example Cl, Br and I; R and R are defined as for the compounds of formula (I); R" represents hydrogen or an optionally substituted phenyl substituent; Rv represent hydroxy, halo, Ar4, Cj^alkyloxycarbonyl-, Cj^alkyl-, CMalkyloxy- or substituted with halo, wherein Ar4 is defined as for the compounds of formula (I)
Further examples for the synthesis of compounds of formula (I) using anyone of the above mentioned synthesis methods, are provided in the experimental part hereinafter.
Where necessary or desired, any one or more of the following further steps in any order may be performed : (i) removing any remaining protecting group(s);
(ii) converting a compound of formula (I) or a protected form thereof into a further compound of formula (I) or a protected form thereof; (iii) converting a compound of formula (I) or a protected form thereof into a N-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof;
(iv) converting a N-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof into a compound of formula (I) or a protected form thereof;
(v) converting a N-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof into another N-oxide, a pharmaceutically acceptable addition salt a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof;
It will be appreciated by those skilled in the art that in the processes described above the functional groups of intermediate compounds may need to be blocked by protecting groups.
Functional groups which it is desirable to protect include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl groups (e.g. fert-butyldimethylsilyl, ter/-butyldiphenylsilyl or trimethylsilyl), benzyl and tetrahydropyranyl. Suitable protecting groups for amino include tert-butyloxycarbonyl or benzyloxycarbonyl. Suitable protecting groups for carboxylic acid include
Figure imgf000023_0001
or benzyl esters.
The protection and deprotection of functional groups may take place before or after a reaction step.
The use of protecting groups is fully described in 'Protective Groups in Organic Chemistry', edited by J W F McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis' 2nd edition, T W Greene & P G M Wutz, Wiley Interscience (1991).
Additionally, the Ν-atoms in compounds of formula (I) can be methylated by art- known methods using CH3-I in a suitable solvent such as, for example 2-propanone, tetrahydrofuran or dimethylformamide.
The compounds of formula (I), can also be converted into each other following art- known procedures of functional group transformation of which some examples are mentioned hereinabove. The compounds of formula (I), may also be converted to the corresponding N-oxide forms following art-known procedures for converting a trivalent nitrogen into its N-oxide form. Said N-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with 3-phenyl-2-(phenylsulfonyl)oxaziridine or with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alky Hydroperoxides, e.g. t-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydro¬ carbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
Pure stereochemically isomeric forms of the compounds of formula (I), may be obtained by the application of art-known procedures. Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g. counter-current distribution, liquid chromatography and the like.
Some of the compounds of formula (I), and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical' methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically.
An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase. Some of the intermediates and starting materials as used in the reaction procedures mentioned hereinabove are known compounds and may be commercially available or may be prepared according to art-known procedures.
The compounds of the present invention are useful because they possess pharmacological properties. They can therefore be used as medicines, in particular to treat pain, in particular post-operative paind and pathologies associated with neuronal death, such as, stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Pick's disease, fronto-temporal dementia, progressive nuclear palsy, corticobasal degeneration, cerebro- vascular dementia, multiple system atrophy, argyrophilic grain dementia, and other tauopathies. Further conditions involving neurodegenerative processes are for instance, age-related macular degeneration, narcolepsy, motor neuron diseases, prion diseases, traumatic nerve injury and repair, and multiple sclerosis.
As described in the experimental part hereinafter, the neurotrophic activity of the present compounds on p75 mediated neuronal death has been demonstrated in vitro, in an assay that determines the survival effect of the compounds on chick DRG neurons using the neurotrophic factor NGF as internal reference. This assay is based on a fluorimetric Calcein-AM measurement and addresses the functional response of neurons as a quantitative measure of survival.
Accordingly, the present invention provides the compounds of formula (I) and their pharmaceutically acceptable N-oxides, addition salts, quaternary amines and stereochemically isomeric forms for use in therapy. More particular in the treatment or prevention of neurodegenerative mediated disorders. The compounds of formula (I), and their pharmaceutically acceptable N-oxides, addition salts, quaternary amines and the stereochemically isomeric forms may hereinafter be referred to as compounds according to the invention.
In view of the utility of the compounds according to the invention, there is provided a method for the treatment of an animal, for example, a mammal including humans, suffering from a neurodegenerative disorder such as stroke, Alzheimer's disease, ALS, epilepsy, SCI, MS, MΝD and other neurodegenerative diseases as mentioned hereinbefore, which comprises administering an effective amount of a compound according to the present invention. Said method comprising the systemic or topical administration of an effective amount of a compound according to the invention, to warm-blooded animals, including humans.
It is thus an object of the present invention to provide a compound according to the present invention for use as a medicine. In particular to use the compound according to the present invention in the manufacture of a medicament for treating pathologies associated with neuronal death such as for example, stroke, Alzheimer's disease, ALS, epilepsy, SCI, MS, MND and other neurodegenerative diseases as mentioned hereinbefore.
In yet a further aspect, the present invention provides the use of the compounds according to the invention in the manufacture of a medicament for treating any of the aforementioned neurodegenerative disorders- or indications.
The amount of a compound according to the present invention, also referred to here as the active ingredient, which is required to achieve a therapeutical effect will be, of course, vary with the particular compound, the route of administration, the age and condition of the recipient, and the particular disorder or disease being treated. A suitable daily dose would be from 0.001 mg/kg to 500 mg/kg body weight, in particular from 0.005 mg/kg to 100 mg/kg body weight. A method of treatment may also include administering the active ingredient on a regimen of between one and four intakes per day.
While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition. Accordingly, the present invention further provides a pharmaceutical composition comprising a compound according to the present invention, together with a pharmaceutically acceptable carrier or diluent. The carrier or diluent must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
The pharmaceutical compositions of this invention may be prepared by any methods well known in the art of pharmacy, for example, using methods such as those described in Gennaro et al. Remington's Pharmaceutical Sciences (18th ed., Mack Publishing Company, 1990, see especially Part 8 : Pharmaceutical preparations and their Manufacture). A therapeutically effective amount of the particular compound, in base form or addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for systemic administration such as oral, percutaneous, or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions: or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharma¬ ceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example; may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, a£ a spot-on or as an ointment. As appropriate compositions for topical application there may be cited all compositions usually employed for topically administering drugs e.g. creams, gellies, dressings, shampoos, tinctures, pastes, ointments, salves, powders and the like. Application of said compositions may be by aerosol, e.g. with a propellent such as nitrogen, carbon dioxide, a freon, or without a propellant such as a pump spray, drops, lotions, or a semisolid such as a thickened composition which can be applied by a swab. In particular, semisolid compositions such as salves, creams, gellies, ointments and the like will conveniently be used.
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, waters, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
In order to enhance the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions, it can be advantageous to employ α-, β- or γ-cyclo- dextrins or their derivatives. Also co-solvents such as alcohols may improve the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions. In the preparation of aqueous compositions, addition salts of the subject compounds are obviously more suitable due to their increased water solubility.
Experimental part
Hereinafter, theierm 'RT' means room temperature, 'MIK' means 4-methyl-2- pentanone,'THF' means tetrahydrofuran, 'DIPE' means diisopropyl ether, 'DMSO' means dimethylsulfoxide.
A. Preparation of the intermediates Example Al a) Preparation of intermediate (1)
Figure imgf000028_0001
A mixture of l-(phenylmethyl)-4-piperidinone (0.1 mol), 3-pyridinamine (0.125 mol) and 4-methylbenzenesulfonic acid (catalytic quantity) in toluene (150 ml) was stirred for 5 hours using a water separator. The solvent was evaporated. The residue (oil) was dissolved in DIPE, filtered and the filtrate's solvent was evaporated, yielding 27 g of intermediate (1). b) Preparation of ^^ p^ intermediate (2)
Intermediate (1) (0.1 mol) was stirred in ethanol (50 ml). Sodium tetrahydroborate (0.1 mol) was added and the reaction mixture was warmed to 500C. Upon completion, the solvent was evaporated. The oily residue was stirred in 1 N HCl (150 ml), then filtered. The filtrate was alkalised with NH4OH, then extracted with toluene. The separated organic layer was dried (MgSO4), filtered and the solvent evaporated. The residue was washed with DIPE, then dried in vacuo, yielding 14 g of intermediate (2);
intermediate (3)
Figure imgf000028_0002
A mixture of intermediate (2) (0.4 mol) andN,N-diethylethanamine (1.6 mol) in benzene (2400 ml) was stirred in a 5-L reaction flask. A solution of 4-methoxybenzoyl chloride (0.8 mol) in benzene (1000 ml) was added dropwise (exothermic temperature rise). The reaction mixture was warmed gently to reflux temperature, then stirred and refluxed overnight. The mixture was cooled, filtered and the filtrate was evaporated. The residue was dissolved in MIK. This solution was washed with a diluted NaOH solution (2 x), then with water (2 x). The organic layer was separated, dried, filtered and the solvent was partially evaporated. The concentrate (± 500 ml) was extracted three times with acidic water. The acidic water layer was extracted once with CHCl3. The CHCI3 layer was extracted three times with acidic water. AU acidic water layers were combined, then washed Ix with DIPE. The water layer was alkalised with a dilute NaOH solution. The aqueous layers were extracted twice with CHCI3. The separated organic layer was washed with water,; dried (MgSO4), filtered and the solvent evaporated. The residue was crystallized from CH3OH, filtered off and dried, yielding 22 g of intermediate (3).
d) Preparation of intermediate (4)
Figure imgf000029_0001
A mixture of intermediate (3) (0.18 mol) in methanol (500 ml) was hydrogenated with palladium on activated carbon (10%) (10 g) as a catalyst. After uptake of hydrogen (1 equiv.), the catalyst was filtered off and the filtrate was evaporated, yielding 62 g of intermediate (4). ..
Example A2 a) Preparation of ^^o^^^^-^s^^? intermediate (5)
Bromine (0.3 mol) was added dropwise to a mixture of 4-[[[(4-fluorophenyl)amino]- thioxomethyl]methylammo]-l-piperidinecarboxylic acid, ethyl ester [104605-22-3](0.3 mol) in tetrachloromethane (600 ml). The reaction mixture was stirred for one hour at room temperature, then it was heated to reflux temperature. The reaction mixture was stirred and refluxed for 3 hours (HBr gas evolution). The mixture was cooled. The solvent (CCl4) was decanted off, yielding 101g of intermediate (5)(quantitative yield; used in next reaction step, without further purification).
b) Preparation of \ X-^J intermediate (6)
A mixture of intermediate (5) (0.3 mol) in a hydrobromic acid solution in water (48%) (800 ml) was stirred and refluxed for 6 hours, then stood over the weekend at room temperature. The solvent was evaporated. The residue was stirred in boiling 2- propanol, cooled and the resulting precipitate was filtered off and dried. The solid was dissolved in water (600 ml), alkalized with 50% NaOH, then extracted with dichloromethane. The separated organic layer was dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent 1 : CH2C12/CH3OH 98/2, then eluent 2: CHC13/CH3OH/NH4OH 85/10/5). The product fractions were collected and the solvent was evaporated, yielding 31 g (39%) of intermediate (6).
Example A3
•s^****Ct ^ lvr ***^-''*'"' ^S"W-*^^S*^^' 'T^^**-! a) Preparation of I \ JwJ intermediate (7) A mixture of 4-(methylamino)-l-piperidinecarboxylic acid, ethyl ester [73733-69-4] (0.2 mol), 2-(chloromethyl)benzothiazole [37859-43-1] (0.22 mol) and sodium : carbonate (0.4 mol) in DMF (400 ml) was stirred overnight at 66°C, then the reaction mixture was poured out into ice water and extracted with dichloromethane. The organic layer was separated, dried, filtered off and the solvent was evaporated. The residue was purified by column chromatography (eluent: CH2CI2/CH3OH 99/1). The product fractions were collected and the solvent was evaporated. The obtained residue was crystallised from 2-propanol and the resulting precipitate was collected, yielding 32.5g (48.7 %) of intermediate (7); m.p.lO1.9°C.
b) Preparation of N-"^^ HCI intermediate (8) A mixture of intermediate (7) (0.05 mol) and potassium hydroxide (0.5 mol) in 2- propanol (350 ml) was stirred and refiuxed for 5 hours and then the solvent was evaporated. Water was added to the residue and the resulting mixture was extracted with dichloromethane. The organic layer was separated, dried, filtered off and the solvent was evaporated. The obtained residue was dissolved in 2-propanol and acidified with HCl/2-propanol and then the resulting hydrochloric acid salt (1:2) was collected, yielding 6.6g (38.4 %) of intermediate (8); m.p. 205.00C.
Example A4 a) Preparation of intermediate (9)
Figure imgf000030_0001
A mixture of 4-[(aminothioxomethyl)amino]-l-piperidinecarboxylic acid, ethyl ester [294622-57-4] (0.1 mol) and 2-bromo-l-(3-methylphenyl)ethanone [51012-64-7] (0.11 mol) in ethanol (300 ml) was stirred and refiuxed overnight. The solvent was evaporated. The residue was washed with DEPE, yielding 42.6g of intermediate (9) (quantitative yield; used in next reaction step, without further purification).
b) Preparation of intermediate (10)
Figure imgf000031_0001
A mixture of intermediate (9) (0.1 mol) in hydrobromic acid (48%) (200 ml) was stirred and refluxed for 30 minutes, then allowed to cool and crystallize out while stirring. The precipitate was filtered off, washed with 2-propanone/DIPE, filtered off and dried, yielding 33g of intermediate (10); m.p. 258°C.
Example A5
a) Preparation of
Figure imgf000031_0002
intermediate (11)
4-(trifluoromethoxy)benzenamine (0.141 mol) dissolved in THF (50ml) was added dropwise to a solution of 4-isothiocyanato-l-piperidinecarboxylic acid, ethyl ester [73733-70-7] (0.15 mol) in THF (200ml) and the mixture was stirred at room temperature overnight. The precipitate was filtered off and dried, yielding 51.6g (93.5%) of interme b) Preparation of
Figure imgf000031_0003
Hα intermediate (12)
Bromine (0.05 mol) was added dropwise (slowly) at 500C to a mixture of intermediate (11) (0.05 mol) in a solution of hydrobromic acid in water (48%)(150ml). The mixture was warmed up till reflux anct stirred and refluxed for 6 hours. The mixture was cooled with stirring and crystallized. The precipitate was filtered off and dried. The filtrate was evaporated, taken up in water, alkalized with NH4OH and extracted with dichloromethane. The organic layer was dried, filtered off and evaporated. The residue was dissolved in 2-propanone and converted into the hydrochloric acid salt (1:2) in 2-propanol, yielding 1.8g (9.2%) of intermediate (12); m.p. 259°C.
Example A6 o s a) Preparation of H H intermediate (13)
Hydrazine monohydrate(0.1 mol) was added dropwise to a mixture of 4-isothiocyanato- 1-piperidinecarboxylic acid ethyl ester [73733-70-7] (0.05 mol) in THF (200 ml) and the reaction mixture was stirred overnight at room temperature, then the mixture was stirred and refluxed for 30 minutes. After cooling, the resulting precipitate was filtered off and dried, yielding 8.8 g (71.9 %) of intermediate (13). b) Preparation of intermediate (14)
Figure imgf000032_0001
A mixture of intermediate (13) (0.1 mol) and benzaldehyde (0.1 mol) in ethanol (200 ml) was stirred and refiuxed overnight and then the solvent was evaporated, yielding 33.5 g (100 %) of intermediate (14).
c) Preparation of ° N H S I^jl intermediate (15)
A mixture of intermediate (14) (0.1 mol) and Iron chloride, hydrate (1:6) (0.36 mol) in water (300 ml) was stirred and refiuxed over the weekend and the solvent was evaporated. The residue was neutralised with a 10 % K2CO3 solution and the resulting mixture was extracted with dichloromethane. The organic layer was separated, dried, filtered off and the solvent was evaporated, yielding 28.6 g (86 %) of intermediate (15).
/***■». Il Il d) Preparation of H I j intermediate (16)
A mixture of intermediate (15) (0.0255 mol) in hydrobromic acid (48%) (100 ml) was stirred and refiuxed for 30 minutes and the solvent was evaporated. The residue was converted into the free base with NH4OH and was extracted with dichloromethane. The organic layer was separated, dried, filtered off and the solvent was evaporated, yielding 6 g (90.2 %) of intermediate (16).
Example A7
I H a) Preparation of g | Jf J intermediate (17)
A solution of l-isothiocyanato-2-methylbenzene (0.185 mol) in DIPE (100 ml) was added dropwise to a solution of 4-(methylamino)-l-piperidinecarboxylic acid, ethyl ester [73733-69-4] (0.185 mol) in DIPE (200 ml). The reaction mixture was stirred for 3 hours. The resulting precipitate was filtered off and dried, yielding 53.6 g (86.5%)of intermediate (17). ' b) Preparation of intermediate (18)
Figure imgf000032_0002
Bromine (0.165 mol) was added dropwise to intermediate (17) (0.16 mol) in hydrobromic acid (48%) (272 ml), stirred at 6O0C. The reaction mixture was heated to reflux temperature, then stirred and refiuxed overnight. The solvent was evaporated. The residue was treated with 50% NaOH and extracted with dichloromethane. The organic layer was separated, dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent: CHCI3/CH3OH 95/5). The product fractions were collected and the solvent was evaporated, yielding 30 g of product. Part (4.0 g) of the free base was dissolved in 2-propanone and converted into the hydrochloric acid salt (1 :2) with HCl/2-propanol. The precipitate was filtered off and dried, yielding 2.5 g of intermediate (18); m.p. 295.50C.
Example A8 a) Preparation of intermediate (19)
Figure imgf000033_0001
A mixture of N-[l-(phenylmethyl)-4-piperidinyl]-3-pyridinamine [63260-34-4] (0.2 mol) and NN-diethylethanamine (0.8 mol) in benzene (1200 ml) was stirred at room temperature. A solution of 4-methyl benzoyl chloride (0.4 mol) in benzene (500 ml) was added dropwise (slightly exothermic reaction) and the resultant reaction mixture was heated slowly to reflux temperature. The mixture was stirred and refluxed for 12 hours, then cooled, filtered and the filtrate was evaporated. The residue was dissolved in CHCl3. The organic solution was washed 3 x with a 10% aqueous NaOH solution, twice with water, dried (MgSO4), filtered and the solvent was evaporated. The residue was dissolved in an HCl solution 1/4 , then stirred for a while. The acidic mixture was washed once with CHCl3. The CHCI3 layer was extracted three times with acidic water. The water layers were combined, washed Ix with DIPE, then alkalized with a 20% aqueous NaOH solution. This mixture was extracted three times with CHCI3. The combinediorganic layers were washed with water, dried (MgSO4), filtered and the solvent was evaporated, yielding 61g of product. Part (4 g) of this product was recrystallized from 2-propanol, filtered off and dried, yielding 3g of intermediate (19);
intermediate (20)
Figure imgf000033_0002
A mixture of intermediate (19) (0.16 mol) in methanol (500 ml) was hydrogenated with palladium on activated carbon (10%) (5 g) as a catalyst. After uptake of hydrogen (1 equiv.), the catalyst was filtered off and the filtrate was evaporated. Part (5 g) of the residue (47 g) was crystallized from 2-propanone/DIPE 1/10, filtered off and dried, yielding 4 g of intermediate (20); m.p. 137.2°C.
Example A9 a) Preparation of
Figure imgf000033_0003
. HBr intermediate (21) A mixture of 4-[(aminothioxomethyl)amino]-l-piperidinecarboxylic acid, ethyl ester [294622-57-4] (0.1 mol) in hydrobromic acid (48%) (200 ml) was stirred and refluxed for 2 hours. The mixture was allowed to cool to room temperature and crystallization resulted. The precipitate was filtered off, washed with DIPE and dried, yielding 15. Ig (47%) of intemediat
b) Preparation of intermediate (22)
Figure imgf000034_0001
A suspension of intermediate (21) (0.05 mol)in ethanol (200 ml) was heated to reflux temperature. At reflux, 3-bromo-2-oxo-propanoic acid, ethyl ester (0.05 mol) was added dropwise (complete dissolution resulted). The reaction mixture was stirred and refluxed overnight. The mixture was allowed to cool to room temperature while stirring. Crystallization resulted and the precipitate was filtered off and dried, yielding 17.6g (84.4%) of intermediate (22); m.p. 236.5°C.
B. Preparation of the compounds Example Bl A mixture of intermediate (4) (0.0066 mol), 1 ,4-dichloro-2-butyne (0.0033 mol) and sodium carbonate (0.68 g) in MIK (20 ml) was stirred overnight at 1000C. The reaction mixture was washed with water (10 ml), and the organic solvent was evaporated. The residue was purified by HPLC over Rromasil silica gel (200 g, 100 A, 5 μm) (eluent: CH2CI2Z(CH2CI2ZCH3OH 9OZlO)ZCH3OH. The pure fractions were collected and the solvent was evaporated, yielding 0.94 g of product. This product was dried, yielding 0.492 g of compound 1.
Example B2
A mixture of N-methyl-N-4-piperidinyl-2-benzothiazolamine (0.0005 mol) and 1,4- diisocyanatobutane (0.5 equiv.) in dichloromethane (5 ml) was stirred overnight at room temperature. The desired compound was isolated and purified by column chromatography over silica gel (eluent: CH2Cl2ZCH3OH gradient from IOOZO to 90Zl 0).
The purest fractions were collected and the solvent was evaporated, yielding 0.062g of compound 2.
Example B3
A mixture of 5-fluoro-N-methyl-N-4-piperidinyl-2-benzothiazolamine (0.01 mol) and
N,N-diethylethanamine (0.012 mol) in dichloromethane(50 ml) was stirred at O0C.
Octanedioyl dichloride (0.005 mol) was added dropwise and the mixture was allowed to warm to room temperature. Stirring was continued overnight. Water was added and this mixture was extracted with dichloromethane. The separated organic layer was dried, filtered and the solvent evaporated. The residue was stirred in DIPE, filtered off and dried, yielding 1.67 g (50%) of compound 3.
Example B4 A solution of l,3-dihydro-l-methyl-3-(4-piperidinyl)-2H-benzimidazol-2-one (0.0005 mol) in dichloromethane (2 ml) was mixed with a solution of N,N-diethylethanamme (0.0006 mol) in dichloromethane (1 ml). This mixture was treated dropwise with a solution of 4,4'-oxybisbenzenesulfonyl chloride (0.00025 mol) in TΗF (1 ml) and the resulting reaction mixture was stirred overnight under atmospheric conditions. The desired compound was isolated and purified by high-performance liquid chromatography over Kromasil Spherical underivated silica gel (55 g, 60 A, 5 μm; eluent: CH2Cy(CH2CyCH3OH 9/l)/CH3OH. The desired fractions were collected and the solvent was evaporated, yielding 0.140 g of compound 4.
Table F-I lists the compounds that were prepared according to one of the above Examples.
Table F-I
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Compound identification
The compounds were identified by LC/MS using a gradient elution system on a reversed phase HPLC. The compounds are identified by their specific retention time and their protonated molecular ion MH+ peak. The HPLC gradient was supplied by a Waters Alliance HT 2790 system with a columnheater set at 400C. Flow from the column was split to a Waters 996 photodiode array (PDA) detector and a Waters- Micromass ZQ mass spectrometer with an electrospray ionization source operated in positive and negative ionization mode. Reversed phase HPLC was carried out on a Xterra MS Cl 8 column (3.5 μm, 4.6 x 1 OO mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammoniumacetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 6.5 minutes, to 100 % B in 1 minute, 100% B for 1 minute and reequilibrate with 100 % A for 1.5 minutes. An injection volume of 10 μL was used.
Mass spectra were acquired by scanning from 100 to 1000 in Is using a dwell time of 0.1 s. The capillary needle voltage was 3kV and the source temperature was maintained at 1400C . Nitrogen was used a the nebulizer gas. Cone voltage was 10 V for positive ionzation mode and 20 V for negative ionization mode. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
Table : retention time (RT in minutes) and molecular weight as the MH+
Figure imgf000038_0001
C. Pharmacological examples Example Cl : Neuronal Viability Assay
Primary culture of chicken dorsal root ganglion neurons Dorsal root ganglia were dissected from White Leghorn chick embryos at embryonic day 10 as described previously (Skaper S. D. and Varon S. (1986) Brain Research 389, 39-46). The ganglia were trypsinised and dissociated by mild trituration in a HBSS buffer supplemented with 0.6% glucose and 0.08% trypsin. To remove non-neuronal cells by differential attachment to culture plastic, the ganglionic cell suspension was diluted to 2.5x105 cells/ml and seeded on tissue culture plastic dishes at 10 ml per 100 mm dish. After 2 h preplating, unattached neurons were collected and resuspended into Basal Eagle Medium containing 10 % FCS. To remove cell aggregates, the cell suspension was passed through a nylon mesh (50 μM) pore diameter. Neuron-enriched cell suspension was plated at 5x104 cells/ml into poly-L-ornithine (100 μg/ml) and laminine (1 μg/ml) coated multiwell 96 plates. Compounds were dissolved in dimethyl sulfoxide and kept as a stock at -200C. NGF and compounds were diluted in the culture medium and added to the cells immediately after plating. The final concentration of dimethyl sulfoxide in the test medium was 0.1%. After two days of incubation, neuronal viability was assessed with calcein-AM.
Neuronal viability assay using calcein-AM
Neuronal viability assay using calcein AM was performed as previously described (Bozyczko-Coyne D., McKenna B. W., Connors T. J., and Neff N. T. (1993) Journal of Neuroscience Methods 50, 205-216). For the assay, calcein-AM was diluted in PBS to the final concentration (1 μM). For each experiment an aliquot of calcein-AM (1 mg/ml in DMSO stored at -2O0C) was thawed immediately before use. The medium was removed from the wells and replaced with the calcein-AM solution. Assay plates were incubated for 1 h at 37°C in a humidified CO2 incubator. Following the incubation, reading was done in a Cytofluor II at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Each plate had control wells with no neurotrophic factor added (0% survival) and wells with 10 ng/ml NGF (100% survival). The drugs to be tested were taken from a stock solution and tested at a final concentration ranging from - 10"5M to 3.10"9M. From the thus obtained dose response curves, the pIC50 value was calculated and scored as follows; Score 1 = pIC50 value < 6, Score 2 = pIC50 value in the range of 6 to 8, Score 3 = pIC50 value >8. Some of the thus obtained results are summarized in the table below.
Figure imgf000040_0002
Figure imgf000040_0001
D. Composition examples
The following formulations exemplify typical pharmaceutical compositions suitable for systemic or topical administration to animal and human subjects in accordance with the present invention. "Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I) or a pharmaceutically acceptable addition salt thereof.
Example D.I : film-coated tablets
PFeparMon.oftøblet.core
A mixture of A.I. (100 g), lactose (570 g) and starch (200 g) was mixed well and thereafter humidified with a solution of sodium dodecyl sulfate (5 g) and polyvinyl¬ pyrrolidone (10 g) in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added microcrystalline cellulose (100 g) and hydrogenated vegetable oil (15 g). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient. Coating
To a solution of methyl cellulose (10 g) in denaturated ethanol (75 ml) there was added a solution of ethyl cellulose (5 g) in CH2Cl2 (150 ml). Then there were added CH2Cl2 (75 ml) and 1,2,3-propanetriol (2.5 ml). Polyethylene glycol (10 g) was molten and dissolved in dichloromethane (75 ml). The latter solution was added to the former and then there were added magnesium octadecanoate (2.5 g), polyvinyl-pyrrolidone (5 g) and concentrated color suspension (30 ml) and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Claims

Claims
1. A compound having the formula
Figure imgf000042_0001
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
n represents 1 or 2; m represents 0, 1, 2 or 3; Z represent C, Ν or O;
-X- represents C2-4alkynyl, Q-nalkyl optionally substituted with hydroxy or X represents a divalent radical of the formula
Figure imgf000042_0002
(a) (b) (C)
wherein; -X]- represents Q-nalkyl, phenyl or a divalent radical selected from the group consisting of
Figure imgf000042_0003
-X2- represents Ci-πalkyl, Ci-4alkyloxyCi^alkyl, phenyl or a divalent
Figure imgf000042_0004
-X3- represents phenyl or a divalent radical selected from the group consisting of
Figure imgf000042_0005
R1 and R2 each independently represents hydrogen,
Figure imgf000043_0001
, Ar'-carbonyl-, Het1, Ar2 or CMalkyl-carbonyl- substituted with Het2 or Ar3; or R1 and R2 taken together with the nitrogen atom with which they are attached form a heterocycle selected from pyrimidinyl, indolyl, indolinyl, indazolyl, imidazolinyl, imidazolidinyl, benzoxazolyl, benzimidazolyl, quinazolinyl, quinolinyl or benzthiazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of carbonyl, Ar5, amino, mono- or di-substituted (Ci-4alkyl)-amino-, hydroxy, halo, polyhaloC1-4alkyloxy-, C^alkyl, Ci^alkyloxycarbonyl- and phenyl ; R independently represents hydroxy or C^alkyloxy-;
Het1 represents a heterocycle selected from pyridinyl, indolinyl, benzimidazolyl, benzthiazolyl, thiazolyl, pyridinyl, benzisoxazolyl, benzoxazolyl, oxadiazolyl or thiadiazolyl wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Ar , CMalkyloxycarbonyl-,
Figure imgf000043_0002
and Ci-4alkyloxy- substituted with halo;
Het2 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, benzisoxazolyl, benzoxazolyl or thiadiazolyl wherein said Het2 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Het4,
Figure imgf000043_0003
substituted with halo; Het3 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl; Het4 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or Ihiadiazolyl wherein said Het4 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, C]-4alkyl- and
Figure imgf000043_0004
Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo, amino, Het3, C^alkylcarbonyl-, Ci^alkyl, Ci^alkyloxy- or C^alkyl substituted with one, two or three halo substituents; in particular Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo, C1-4alkyl or Ci^alkyloxy-;
Ar4 represents phenyl optionally substituted with halo,
Figure imgf000043_0005
Ci^alkyloxy- or Ci^alkyl substituted with one, two or three halo substituents;
Ar5 represents phenyl optionally substituted with C1-4alkyloxy- or Cs-βcycloalkyloxy-.
2. A compound according to claim 1 wherein; n represents 1; m represents 0, 1 or 2; in particular m represents 0;
R1 and R2 each independently represent hydrogen, C1-4alkyl, Ar'-carbonyl, Het1,
Ar2 or Ci-4alkylcarbonyl optionally substituted with Het2 or Ar3; or R1 and R2 taken together with the nitrogen atom to which they are attached form a heterocycle selected from indolyl, indolinyl, benzimidazolyl, benzthiazolyl, benzisoxazolyl or oxodiazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy,
Figure imgf000044_0002
carbonyl,
Figure imgf000044_0001
Ar5 and halo;
Het ' represents a heterocycle selected from pyridinyl, indolinyl, indolyl, benzthiazolyl, benzimidazolyl, thiazolyl, thiadiazolyl or benzisoxazolyl wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of halo, Ar4, C1. 4alkyloxycarbonyl-, C^alkyl and C1-4alkyloxy-, said C^alkyloxy- being optionally substituted with halo;
Het2 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl;
Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo,
Figure imgf000044_0003
substituted with one, two or three halo substituents;
Ar4 represents phenyl optionally substituted with halo,
Figure imgf000044_0004
or d^alkyl substituted with one, two or three halo substituents;
Ar5 represents phenyl optionally substituted with C^alkyloxy- or Cs-βcycloalkyloxy-.
3. A compound according to claim 1 wherein; n represents 1 or 2; m represents 0, 1, 2 or 3; Z represent CH2;
-X- represents C2-4alkynyl, Ci_i2alkyl optionally substituted with hydroxy or X represents a divalent radical of the formula
Figure imgf000044_0005
(a) (b) (C) wherein; -Xr repre from the group
consisting
Figure imgf000045_0001
phenyl or a divalent
Figure imgf000045_0002
-X3- represents phenyl or a divalent radical selected from the group
consisting of
Figure imgf000045_0004
Figure imgf000045_0003
R1 and R2 each independently represents hydrogen, Ci-4alkyl, Cwalkyl-carbonyl- , Ar'-carbonyl-, Het1, Ar2 or CMalkyl-carbonyl- substituted with Het2 or Ar3; or R1 and R2 taken together with the nitrogen atom with which they are attached form a heterocycle selected from pyrimidinyl, indolyl, indolinyl, indazolyl, imidazolinyl, imidazolidinyl, benzoxazolyl, benzimidazolyl, quinazolinyl, quinolinyl or benzthiazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of carbonyl, Ar5, amino, mono- or di-substituted (Ci.4alkyl)-amino-, hydroxy, halo,
Figure imgf000045_0005
and phenyl ; R3 independently represents hydroxy or
Figure imgf000045_0006
Het1 represents a heterocycle selected from pyridinyl, indolinyl, benzimidazolyl, benzthiazolyl, thiazolyl, pyridinyl, benzisoxazolyl, benzoxazolyl, oxadiazolyl or thiadiazolyl wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Ar4,
Figure imgf000045_0007
and C1-4alkyloxy- substituted with halo; Het2 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, benzisoxazolyl, benzoxazolyl or thiadiazolyl wherein said Het2 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, Het4, Cmalkyloxycarbonyl-, Chalky!-,
Figure imgf000045_0008
and
Figure imgf000045_0009
substituted with halo;
Het3 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl; HeI4 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl wherein said Het4 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo,
Figure imgf000046_0001
Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo, amino, Het3, Cmalkylcarbonyl-, C^alkyl, d^alkyloxy- or Ci^alkyl substituted with one, two or three halo substituents; in particular Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo,
Figure imgf000046_0002
or CMalkyloxy-; Ar4 represents phenyl optionally substituted with halo,
Figure imgf000046_0003
C^alkyloxy- or
C^alkyl substituted with one, two or three halo substituents; Ar5 represents phenyl optionally substituted with
Figure imgf000046_0004
or Cs-δcycloalkyloxy-.
A compound according to claim 1 wherein; n represents 1; m represents 0; Z represents CH2;
R1 and R2 each independently represent hydrogen,
Figure imgf000046_0005
Het1, Ar2 or CMalkylcarbonyl optionally substituted with Het2 or Ar3; or
R1 and R2 taken together with the nitrogen atom to which they are attached form a heterocycle selected from indolyl, indolinyl, benzimidazolyl, benzthiazolyl, benzisoxazolyl or oxodiazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, Ci-4alkyl, carbonyl, CMalkyloxycarbonyl-,
Ar5 and halo;
Het l represents a heterocycle selected from pyridinyl, indolinyl, indolyl, benzthiazolyl, benzimidazolyl, thiazolyl, thiadiazolyl or benzisoxazolyl wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of halo, Ar4,
CMalkyloxycarbonyl-,
Figure imgf000046_0006
said CMalkyloxy- being optionally substituted with halo; Her2 represents a heterocycle selected from thiophenyl, furanyl, pyrrolyl, pyridinyl, thiazolyl, oxazolyl, pyridinyl, or thiadiazolyl; Ar1, Ar2 and Ar3 each independently represent phenyl optionally substituted with halo, Ci-4alkyl, Cmalkyloxy- or Ci^alkyl substituted with one, two or three halo substituents; Ar4 represents phenyl optionally substituted with halo, Ci^alkyl, C1-4alkyloxy- or Cualkyl substituted with one, two or three halo substituents;
Ar5 represents phenyl optionally substituted with C^alkyloxy- or
Ca-βcycloalkyloxy-.
5. A compound according to claim 1 wherein; n represents 1; m represents 0; Z represents CH2; R1 and R2 each independently represents hydrogen, Ci^alkyl, Ar1 -carbonyl-, Het1,
Ar2 or Q^alkylcarbonyl- substituted with Het2 or Ar3; or R and R2 taken together with the nitrogen atom to which they are attached form a heterocycle selected from indolyl, indolinyl, or benzimidazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of carbonyl, hydroxy or halo;
Het1 represents a heterocycle selected from pyridinyl, indolinyl, benzthiazolyl, thiazolyl, or thiadiazolyl, wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of halo, Ar4, C i^alkyloxy carbonyl- and Ci^alkyloxy- substituted with halo; Het2 represents thiophenyl;
Ar1 represents phenyl optionally substituted with halo or
Figure imgf000047_0001
Ar2 represents phenyl optionally substituted with halo or CMalkyloxy; Ar3 represents phenyl optionally substituted with halo or CMalkyl; or Ar4 represents phenyl optionally substituted with
Figure imgf000047_0002
6. A compound according to claims 1 or 2 wherein; m represents 0;
Z represents CH2; n represents 1; -X- represents C2-4alkynyl, Q-^alkyl optionally substituted with hydroxy or -X- represents a divalent radical of the formula (a), (b) or (c) as defined hereinbefore wherein; -Xj- represents Ci-12alkyl or a divalent radical selected from (d) or (e) as defined for the compounds of formula (I) hereinbefore; -X2- represents Ci-12alkyl,
Figure imgf000047_0003
phenyl or a divalent radical of formula (g) as defined for the compounds of formula (I) hereinbefore; -X3- represents phenyl or a divalent radical selected from the (g), (h) and (i) as defined for the compounds of formula (I) hereinbefore; R1 and R2 each independently represent hydrogen, Ci-4alkyl or R1 and R2 taken together with the nitrogen atom to which they are attached form a heterocycle selected from indolyl, indolinyl or benzimidazolyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from the group consisting of carbonyl, hydroxy or halo;
Het1 represents a heterocycle selected from pyridinyl, indolinyl or benzthiazolyl wherein said Het' is optionally substituted with halo, Ar4 or polyhaloC^alkyloxy-;
Her2 represents thiophenyl;
Ar1 represents phenyl optionally substituted with halo or Q^alkyloxy-;
Ar2 represents phenyl optionally substituted with halo or Ci^alkyloxy;
Ar3 represents phenyl optionally substituted with halo or Ci-4alkyl; or
Ar4 represents phenyl optionally substituted with C^alkyl-.
7. A compound according to any one of claims 1 or 4 wherein; Ar2 represents phenyl substituted with halo
8. A compound as claimed in claim 1 wherein the compound is selected from the compounds with formulae (A) - (O) below:
Figure imgf000048_0001
Figure imgf000049_0001
9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutic effective amount of a compound as described in any one of claims 1 to 6.
10. A process of preparing a pharmaceutical composition as defined in claim 4, characterized in that, a pharmaceutically acceptable carrier is intimately mixed with a therapeutic effective amount of a compound as described in any one of claims 1 to 6.
11. A compound as claimed in any one of claims 1 to 6 for use as a medicine.
12. Use of a compound as claimed in any one of claims 1 to 6 in the manufacture of a medicament for treating pain, in particular post-operative pain and pathologies associated with neuronal death, such as, stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Pick's disease, fronto- temporal dementia, progressive nuclear palsy, corticobasal degeneration, cerebro¬ vascular dementia, multiple system atrophy, argyrophilic grain dementia, other tauopathies, and further conditions involving neurodegenerative processes are for instance, age-related macular degeneration, narcolepsy, motor neuron diseases, prion diseases, traumatic nerve injury and repair, and multiple sclerosis.
PCT/EP2005/053345 2004-07-16 2005-07-13 Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitabale for the treatment of neurodegenerative disorders WO2006008259A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP05769847A EP1771445A1 (en) 2004-07-16 2005-07-13 Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitabale for the treatment of neurodegenerative disorders
JP2007520836A JP2008506669A (en) 2004-07-16 2005-07-13 Piperidine, piperazine or morpholine dimer compounds suitable for the treatment of neurodegenerative diseases or their 7-membered homologs
MX2007000615A MX2007000615A (en) 2004-07-16 2005-07-13 Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitabale for the treatment of neurodegenerative disorders.
CA002572821A CA2572821A1 (en) 2004-07-16 2005-07-13 Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitable for the treatment of neurodegenerative disorders
AU2005263718A AU2005263718A1 (en) 2004-07-16 2005-07-13 Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitabale for the treatment of neurodegenerative disorders
EA200700140A EA200700140A1 (en) 2004-07-16 2005-07-13 DIMERAL COMPOUNDS OF PIPERIDINE, PIPERAZINE OR MORPHOLINE OR THEIR SEVENTIVE ANALOGUES INTENDED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
US11/632,510 US20070299109A1 (en) 2004-07-16 2005-07-13 Dimeric Compounds Of Piperidine, Piperazine Or Morpholine Or Their 7-Membered Analogs Suitable For The Treatment Of Neurodegenerative Disorders
IL180703A IL180703A0 (en) 2004-07-16 2007-01-15 Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitable for the treatment of neurodegenerative disorders
NO20070884A NO20070884L (en) 2004-07-16 2007-02-16 Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogues suitable for the treatment of neurodegenerative disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58844604P 2004-07-16 2004-07-16
US60/588,446 2004-07-16
EP04103413 2004-07-16
EP04103413.3 2004-07-16

Publications (1)

Publication Number Publication Date
WO2006008259A1 true WO2006008259A1 (en) 2006-01-26

Family

ID=34929341

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/053345 WO2006008259A1 (en) 2004-07-16 2005-07-13 Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitabale for the treatment of neurodegenerative disorders

Country Status (8)

Country Link
US (1) US20070299109A1 (en)
EP (1) EP1771445A1 (en)
KR (1) KR20070036148A (en)
CN (1) CN1984910A (en)
AU (1) AU2005263718A1 (en)
CA (1) CA2572821A1 (en)
NO (1) NO20070884L (en)
WO (1) WO2006008259A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544633A (en) * 2006-07-27 2009-12-17 フダン ユニバーシティー Divalent (-)-meptazinol compound and / or salt thereof, production method and use
WO2014116845A1 (en) * 2013-01-23 2014-07-31 Novartis Ag Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104226A1 (en) * 2002-06-07 2003-12-18 Sanofi-Synthelabo Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104226A1 (en) * 2002-06-07 2003-12-18 Sanofi-Synthelabo Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544633A (en) * 2006-07-27 2009-12-17 フダン ユニバーシティー Divalent (-)-meptazinol compound and / or salt thereof, production method and use
WO2014116845A1 (en) * 2013-01-23 2014-07-31 Novartis Ag Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
CN104936955A (en) * 2013-01-23 2015-09-23 诺华股份有限公司 Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions
AU2016256728B2 (en) * 2013-01-23 2018-03-29 Novartis Ag Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions
CN104936955B (en) * 2013-01-23 2018-08-28 诺华股份有限公司 Thiadiazoles analog and treatment lack the method for relevant illness with SMN
EA035606B1 (en) * 2013-01-23 2020-07-15 Новартис Аг Thiadiazole analogs and methods for treating smn-deficiency-related conditions
EP3736271A1 (en) * 2013-01-23 2020-11-11 Novartis AG Thiadiazole analogs and their use for treating diseases associated with a deficiency of smn motor neurons
EP4227304A3 (en) * 2013-01-23 2023-08-30 Novartis AG Thiadiazole analogs and their use for treating diseases associated with a deficiency of smn motor neurons

Also Published As

Publication number Publication date
US20070299109A1 (en) 2007-12-27
AU2005263718A1 (en) 2006-01-26
EP1771445A1 (en) 2007-04-11
CN1984910A (en) 2007-06-20
NO20070884L (en) 2007-02-16
KR20070036148A (en) 2007-04-02
CA2572821A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
AU688120B2 (en) New piperidine compounds, process for their preparation and the pharmaceutical compositions which contain them
DE60125335T2 (en) AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES
AU2004281215B2 (en) Derivatives of N-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
DE60308850T2 (en) PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS
ES2616084T3 (en) Pyrazole compounds as sigma receptor inhibitors
AU2004281214B2 (en) Derivatives of N-``phenyl(piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics
EP3166939B1 (en) Therapeutic compounds and methods of use thereof
DE60122753T2 (en) CYCLOPENTYL MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
CN112312904A (en) Spiro compounds
JP2008510768A (en) Sigma receptor inhibitor
WO2010089127A1 (en) Substituted spiro-amides as b1r modulators
JP2008542249A (en) Aminopiperidine quinoline with antibacterial activity and its stereo-analogues
CA2314008A1 (en) 2-benzimidazolylamine compounds as orl1-receptor agonists
PL207384B1 (en) Benzothiazole derivatives
DE102006049452A1 (en) Substituted tetrahydropyrolopiperazine compounds and their use in medicaments
EP2619178A1 (en) Substituted benzamide compounds
DE60305037T2 (en) PIPERAZINYLACYLPIPERIDIN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
CA3065898A1 (en) Pyrazole magl inhibitors
CA2961033A1 (en) Heterocyclic compound
WO2013170072A2 (en) Compounds for the treatment of neurological disorders
JPS60215683A (en) Novel condensated diazepinone
KR20110000749A (en) Novel class of spiro piperidines for the treatment of neurodegenerative diseases
EP1786775A1 (en) Dimeric piperidine derivates
JP2008506669A (en) Piperidine, piperazine or morpholine dimer compounds suitable for the treatment of neurodegenerative diseases or their 7-membered homologs
EP1771445A1 (en) Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitabale for the treatment of neurodegenerative disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005769847

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2572821

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 344/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580023745.9

Country of ref document: CN

Ref document number: 2007520836

Country of ref document: JP

Ref document number: 180703

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/000615

Country of ref document: MX

Ref document number: 11632510

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 552830

Country of ref document: NZ

Ref document number: 200700140

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1020077001949

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2005263718

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005263718

Country of ref document: AU

Date of ref document: 20050713

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005263718

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020077001949

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005769847

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11632510

Country of ref document: US